Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India · Delayed Price · Currency is INR 32.30
-1.80 (-5.28%)
Dec 8, 2025, 1:40 PM IST
Balaxi Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 2,765 | 2,926 | 2,413 | 3,364 | 2,794 | 2,313 | Upgrade |
Other Revenue | -0 | - | - | - | - | - | Upgrade |
| 2,765 | 2,926 | 2,413 | 3,364 | 2,794 | 2,313 | Upgrade | |
Revenue Growth (YoY) | 4.88% | 21.25% | -28.28% | 20.42% | 20.77% | 406.95% | Upgrade |
Cost of Revenue | 1,522 | 1,659 | 1,289 | 2,072 | 1,980 | 1,728 | Upgrade |
Gross Profit | 1,242 | 1,266 | 1,124 | 1,293 | 814.24 | 585.36 | Upgrade |
Selling, General & Admin | 1,024 | 894.05 | 656.74 | 727.32 | 312.19 | 160.86 | Upgrade |
Other Operating Expenses | - | - | -0.11 | -0.26 | -0.3 | -1.75 | Upgrade |
Operating Expenses | 1,043 | 912.99 | 677.62 | 744.58 | 317.02 | 162.45 | Upgrade |
Operating Income | 199.71 | 353.21 | 446.44 | 548.12 | 497.22 | 422.9 | Upgrade |
Interest Expense | -40.11 | -29.35 | -16.77 | -5 | -1.42 | -0.13 | Upgrade |
Interest & Investment Income | - | - | - | - | - | 0.02 | Upgrade |
Currency Exchange Gain (Loss) | -60.78 | -60.78 | -32.79 | 18.65 | 49.42 | 20.5 | Upgrade |
Other Non Operating Income (Expenses) | 81.3 | 23.61 | 6.21 | 7.46 | - | -0 | Upgrade |
EBT Excluding Unusual Items | 180.12 | 286.7 | 403.09 | 569.22 | 545.22 | 443.29 | Upgrade |
Other Unusual Items | - | - | -382.93 | - | - | - | Upgrade |
Pretax Income | 180.12 | 286.7 | 20.15 | 569.22 | 545.22 | 443.29 | Upgrade |
Income Tax Expense | 35.13 | 35.99 | 44.02 | 109.6 | 68.65 | 61.92 | Upgrade |
Net Income | 145 | 250.7 | -23.87 | 459.63 | 476.58 | 381.37 | Upgrade |
Net Income to Common | 145 | 250.7 | -23.87 | 459.63 | 476.58 | 381.37 | Upgrade |
Net Income Growth | -59.27% | - | - | -3.56% | 24.96% | 524.83% | Upgrade |
Shares Outstanding (Basic) | 55 | 55 | 51 | 50 | 50 | 50 | Upgrade |
Shares Outstanding (Diluted) | 55 | 55 | 51 | 51 | 50 | 50 | Upgrade |
Shares Change (YoY) | 3.60% | 7.26% | 1.69% | 1.23% | - | 32.96% | Upgrade |
EPS (Basic) | 2.62 | 4.54 | -0.46 | 9.16 | 9.53 | 7.63 | Upgrade |
EPS (Diluted) | 2.62 | 4.54 | -0.46 | 9.08 | 9.53 | 7.63 | Upgrade |
EPS Growth | -60.70% | - | - | -4.74% | 24.96% | 369.94% | Upgrade |
Free Cash Flow | -361.44 | -561.23 | 41.74 | -69.83 | 288.23 | -12.74 | Upgrade |
Free Cash Flow Per Share | -6.52 | -10.17 | 0.81 | -1.38 | 5.76 | -0.26 | Upgrade |
Dividend Per Share | - | - | - | - | 0.100 | - | Upgrade |
Gross Margin | 44.94% | 43.28% | 46.58% | 38.42% | 29.14% | 25.30% | Upgrade |
Operating Margin | 7.22% | 12.07% | 18.50% | 16.29% | 17.80% | 18.28% | Upgrade |
Profit Margin | 5.24% | 8.57% | -0.99% | 13.66% | 17.06% | 16.49% | Upgrade |
Free Cash Flow Margin | -13.07% | -19.18% | 1.73% | -2.08% | 10.32% | -0.55% | Upgrade |
EBITDA | 216.73 | 370.3 | 467.42 | 565.64 | 502.34 | 425.88 | Upgrade |
EBITDA Margin | 7.84% | 12.66% | 19.37% | 16.81% | 17.98% | 18.41% | Upgrade |
D&A For EBITDA | 17.02 | 17.1 | 20.98 | 17.53 | 5.12 | 2.98 | Upgrade |
EBIT | 199.71 | 353.21 | 446.44 | 548.12 | 497.22 | 422.9 | Upgrade |
EBIT Margin | 7.22% | 12.07% | 18.50% | 16.29% | 17.80% | 18.28% | Upgrade |
Effective Tax Rate | 19.50% | 12.55% | 218.44% | 19.25% | 12.59% | 13.97% | Upgrade |
Revenue as Reported | 2,785 | 2,888 | 2,386 | 3,391 | 2,844 | 2,336 | Upgrade |
Advertising Expenses | - | 6.41 | 6.55 | 8.41 | 10.21 | 1.02 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.